CYD [CHINA YUCHAI INTERNATIONAL] 6-K: (Original Filing)

[China Yuchai International Announces 2015 Unaudited Fourth Quarter and Full Year Financial Results SINGAPORE, Singapore – February 24, 2016 – China Yuchai International Limited Financial Highlights for the Fourth Quarter of 2015 • Net revenue declined to RMB 2.9 billion (US$ 450.7 million) compared with RMB 3.9 billion in the fourth quarter of 2014; • Gross profit was RMB 692.1] [CHINA YUCHAI INTERNATIONAL LIMITED UNAUDITED CONSOLIDATED INCOME STATEMENTS For the quarters ended December 31, 2015 and 2014 (RMB and US$ amounts expressed in thousands, except per share data) December 31, 2015 December 31, 2014 RMB’000 US$’000 RMB’000 US$’000 Revenue 2,926,451 450,667 3,920,895 603,809 Cost of goods sold (2,234,311 ) (344,079 ) (2,950,802 ) (454,417 ) Gross profit 692,140 106,588 970,093] [TABLE OF CONTENTS 99.1 Press release dated February 24, 2016 – China Yuchai International Announces 2015 Unaudited Fourth Quarter and Full Year Financial Results 99.2 Unaudited Financial Statements for Year Ended December 31, 2015 CHINA YUCHAI INTERNATIONAL LIMITED Weng Ming Hoh President and Director 6-K 1 d147650d6k.htm FORM 6-K]

By | 2016-03-28T11:20:51+00:00 February 24th, 2016|Categories: Chinese Stocks, CYD, SEC Original|Tags: , , , , , |0 Comments
Read More

CYD [CHINA YUCHAI INTERNATIONAL] 6-K: China Yuchai International Announces 2015 Unaudited Fourth Quarter

[China Yuchai International Announces 2015 Unaudited Fourth Quarter and Full Year Financial Results SINGAPORE, Singapore – February 24, 2016 – China Yuchai International Limited Financial Highlights for the Fourth Quarter of 2015 • Net revenue declined to RMB 2.9 billion (US$ 450.7 million) compared with RMB 3.9 billion in the fourth quarter of 2014; • Gross profit was RMB 692.1] [CHINA YUCHAI INTERNATIONAL LIMITED UNAUDITED CONSOLIDATED INCOME STATEMENTS For the quarters ended December 31, 2015 and 2014 (RMB and US$ amounts expressed in thousands, except per share data) December 31, 2015 December 31, 2014 RMB’000 US$’000 RMB’000 US$’000 Revenue 2,926,451 450,667 3,920,895 603,809 Cost of goods sold (2,234,311 ) (344,079 ) (2,950,802 ) (454,417 ) Gross profit 692,140 106,588 970,093] [TABLE OF CONTENTS 99.1 Press release dated February 24, 2016 – China Yuchai International Announces 2015 Unaudited Fourth Quarter and Full Year Financial Results 99.2 Unaudited Financial Statements for Year Ended December 31, 2015 CHINA YUCHAI INTERNATIONAL LIMITED Weng Ming Hoh President and Director 6-K 1 d147650d6k.htm FORM 6-K]

By | 2016-03-28T11:22:52+00:00 February 24th, 2016|Categories: Chinese Stocks, CYD, Webplus ver|Tags: , , , , , |0 Comments
Read More

BSPM [Biostar Pharmaceuticals] 8-K: (Original Filing)

[Biostar Pharmaceuticals Regains Compliance with NASDAQ $1.00 Minimum Bid Price XIANYANG, China, February 24, 2016 -- Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) (“Biostar”), a PRC-based developer, manufacturer and marketer of pharmaceutical and health supplement products in China, today announced that on February 22, 2016, NASDAQ notified the Company that it had regained compliance with continued listing Rule 5550(a)(2), which requires a] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): February 24, 2016 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue, Xianyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]

By | 2016-03-28T17:36:39+00:00 February 24th, 2016|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Read More

BSPM [Biostar Pharmaceuticals] 8-K: Biostar Pharmaceuticals Regains Compliance with NASDAQ $1.00 Minimum

[Biostar Pharmaceuticals Regains Compliance with NASDAQ $1.00 Minimum Bid Price XIANYANG, China, February 24, 2016 -- Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) (“Biostar”), a PRC-based developer, manufacturer and marketer of pharmaceutical and health supplement products in China, today announced that on February 22, 2016, NASDAQ notified the Company that it had regained compliance with continued listing Rule 5550(a)(2), which requires a] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): February 24, 2016 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue, Xianyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]

By | 2016-03-28T17:38:31+00:00 February 24th, 2016|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments
Read More

SGOC [SGOCO] CORRESP: RM 1301, 13/F Golden Centre, NO.188 DES VOEUX

[RM 1301, 13/F Golden Centre, NO.188 DES VOEUX RD CENTRAL, SHEUNG WAN, HONG KONG February 24, 2016 Via EDGAR Christy Adams, Senior Staff Accountant Division of Corporation Finance Re: SGOCO Group, Ltd. Form 20-F for Fiscal Year Ended December 31, 2014 Filed May 15, 2015 File No. 1-35016 Dear Ms. Adams: SGOCO Group, Ltd.(“SGOC” or the “Company” and sometimes referred]

By | 2016-04-01T18:16:46+00:00 February 24th, 2016|Categories: Chinese Stocks, SGOC, Webplus ver|Tags: , , , , , |0 Comments
Read More

ASX [ADVANCED SEMICONDUCTOR ENGINEERING] SC TO-T/A: (Original Filing)

[] [Advanced Semiconductor Engineering, Inc. Investor Relations Contact: Iris Wu, Manager irissh_wu@aseglobal.com Tel: +886.2.6636.5678 http://www.aseglobal.com February 24, 2016 Press Release in connection with ASE’s Tender Offer for SPIL Shares ASE FTC SPIL Tender Offer Taipei, Taiwan, R.O.C., February 24, 2016 – Advanced Semiconductor Engineering, Inc. (TWSE Code: 2311, NYSE Code: ASX) (“ To accommodate the FTC review period for the Tender]

By | 2016-03-20T08:51:39+00:00 February 24th, 2016|Categories: ASX, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Read More
Skip to toolbar